BELLUS Health Inc. (TSX: BLU)
Health Care · Biotechnology · CA
CA$—
— today · — 1Y
BELLUS Health Inc. (TSX: BLU) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores BELLUS Health Inc. across four factors: quality 32/100, growth 0/100. Its strongest factor is quality.
BLU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $15.00K
- P/E
- —
- EPS
- -0.72
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- CA$—
- 52-week low
- CA$—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 74
- Next earnings
- —
About BELLUS Health Inc.
BELLUS Health Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to creating new therapeutic options for intractable chronic cough (RCC) and various other conditions characterized by heightened cough sensitivity. The company's primary investigational compound, BLU-5937, functions as a P2X3 receptor antagonist. This drug is currently progressing through Phase II clinical trials, where it is being assessed for its potential in treating both RCC and persistent itching. Founded in 1993, BELLUS Health Inc. is headquartered in Laval, Canada.
- ISIN
- CA07987C2040
- Founded
- 1993
- Listed since
- Jun 22, 2000
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.